Five Hematology Drug Launches To Look Out For In 2022
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are five new hematology products that could make their market debuts (or return) next year.
You may also be interested in...
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
Accelerated Assessment Success In EU For CSL Behring And Roche
There have been some recent successes on the accelerated assessment front in the EU but more requests are rejected than granted.
Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.